<?xml version='1.0' encoding='utf-8'?>
<document id="25923589"><sentence text="Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies."><entity charOffset="0-9" id="DDI-PubMed.25923589.s1.e0" text="Ritonavir" /><entity charOffset="37-49" id="DDI-PubMed.25923589.s1.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.25923589.s1.e0" e2="DDI-PubMed.25923589.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25923589.s1.e0" e2="DDI-PubMed.25923589.s1.e1" /></sentence><sentence text="The regulatory prohibition of ketoconazole as a CYP3A index inhibitor in drug-drug interaction (DDI) studies has compelled consideration of alternative inhibitors"><entity charOffset="30-42" id="DDI-PubMed.25923589.s2.e0" text="ketoconazole" /></sentence><sentence text="" /><sentence text="The biomedical literature was searched to identify DDI studies in which oral midazolam (MDZ) was the victim, and the inhibitory perpetrator was either ketoconazole, itraconazole, clarithromycin, or ritonavir"><entity charOffset="77-86" id="DDI-PubMed.25923589.s4.e0" text="midazolam" /><entity charOffset="88-91" id="DDI-PubMed.25923589.s4.e1" text="MDZ" /><entity charOffset="151-163" id="DDI-PubMed.25923589.s4.e2" text="ketoconazole" /><entity charOffset="165-177" id="DDI-PubMed.25923589.s4.e3" text="itraconazole" /><entity charOffset="179-193" id="DDI-PubMed.25923589.s4.e4" text="clarithromycin" /><entity charOffset="198-207" id="DDI-PubMed.25923589.s4.e5" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e0" e2="DDI-PubMed.25923589.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e0" e2="DDI-PubMed.25923589.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e0" e2="DDI-PubMed.25923589.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e0" e2="DDI-PubMed.25923589.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e0" e2="DDI-PubMed.25923589.s4.e4" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e0" e2="DDI-PubMed.25923589.s4.e5" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e1" e2="DDI-PubMed.25923589.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e1" e2="DDI-PubMed.25923589.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e1" e2="DDI-PubMed.25923589.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e1" e2="DDI-PubMed.25923589.s4.e4" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e1" e2="DDI-PubMed.25923589.s4.e5" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e2" e2="DDI-PubMed.25923589.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e2" e2="DDI-PubMed.25923589.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e2" e2="DDI-PubMed.25923589.s4.e4" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e2" e2="DDI-PubMed.25923589.s4.e5" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e3" e2="DDI-PubMed.25923589.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e3" e2="DDI-PubMed.25923589.s4.e4" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e3" e2="DDI-PubMed.25923589.s4.e5" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e4" e2="DDI-PubMed.25923589.s4.e4" /><pair ddi="false" e1="DDI-PubMed.25923589.s4.e4" e2="DDI-PubMed.25923589.s4.e5" /></sentence><sentence text=" The ratios (RAUC ) of total area under the curve (AUC) for MDZ with inhibitor divided by MDZ AUC in the control condition were aggregated across individual studies for each inhibitor"><entity charOffset="60-68" id="DDI-PubMed.25923589.s5.e0" text="MDZ" /><entity charOffset="90-98" id="DDI-PubMed.25923589.s5.e1" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.25923589.s5.e0" e2="DDI-PubMed.25923589.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25923589.s5.e0" e2="DDI-PubMed.25923589.s5.e1" /></sentence><sentence text="" /><sentence text="Mean (± SE) RAUC values were: ketoconazole (15 studies, 131 subjects), 11"><entity charOffset="30-42" id="DDI-PubMed.25923589.s7.e0" text="ketoconazole" /></sentence><sentence text="5 (±1" /><sentence text="2); itraconazole (five studies, 48 subjects), 7"><entity charOffset="4-16" id="DDI-PubMed.25923589.s9.e0" text="itraconazole" /></sentence><sentence text="3 (±1" /><sentence text="0); clarithromycin (five studies, 73 subjects), 6"><entity charOffset="4-18" id="DDI-PubMed.25923589.s11.e0" text="clarithromycin" /></sentence><sentence text="5 (±10" /><sentence text="9); and ritonavir (13 studies, 159 subjects), 14"><entity charOffset="8-17" id="DDI-PubMed.25923589.s13.e0" text="ritonavir" /></sentence><sentence text="5 (±2" /><sentence text="0)" /><sentence text=" Differences among inhibitors were significant (F = 5" /><sentence text="31, P &lt; 0" /><sentence text="005)" /><sentence text=" RAUC values were not significantly related to inhibitor dosage or to duration of inhibitor pre-exposure prior to administration of MDZ"><entity charOffset="132-140" id="DDI-PubMed.25923589.s19.e0" text="MDZ" /></sentence><sentence text="" /><sentence text="Ritonavir produces CYP3A inhibition equivalent to or greater than ketoconazole, and is the best index CYP3A inhibitor alternative to ketoconazole"><entity charOffset="0-9" id="DDI-PubMed.25923589.s21.e0" text="Ritonavir" /><entity charOffset="66-78" id="DDI-PubMed.25923589.s21.e1" text="ketoconazole" /><entity charOffset="133-145" id="DDI-PubMed.25923589.s21.e2" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.25923589.s21.e0" e2="DDI-PubMed.25923589.s21.e0" /><pair ddi="false" e1="DDI-PubMed.25923589.s21.e0" e2="DDI-PubMed.25923589.s21.e1" /><pair ddi="false" e1="DDI-PubMed.25923589.s21.e0" e2="DDI-PubMed.25923589.s21.e2" /><pair ddi="false" e1="DDI-PubMed.25923589.s21.e1" e2="DDI-PubMed.25923589.s21.e1" /><pair ddi="false" e1="DDI-PubMed.25923589.s21.e1" e2="DDI-PubMed.25923589.s21.e2" /></sentence><sentence text=" Cobicistat closely resembles ritonavir in structure and function, and can also be considered"><entity charOffset="30-39" id="DDI-PubMed.25923589.s22.e0" text="ritonavir" /></sentence><sentence text=" Itraconazole and clarithromycin are not suitable alternatives since they do not produce inhibition comparable with ketoconazole or ritonavir, and have other significant disadvantages as well"><entity charOffset="1-13" id="DDI-PubMed.25923589.s23.e0" text="Itraconazole" /><entity charOffset="18-32" id="DDI-PubMed.25923589.s23.e1" text="clarithromycin" /><entity charOffset="116-128" id="DDI-PubMed.25923589.s23.e2" text="ketoconazole" /><entity charOffset="132-141" id="DDI-PubMed.25923589.s23.e3" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.25923589.s23.e0" e2="DDI-PubMed.25923589.s23.e0" /><pair ddi="false" e1="DDI-PubMed.25923589.s23.e0" e2="DDI-PubMed.25923589.s23.e1" /><pair ddi="false" e1="DDI-PubMed.25923589.s23.e0" e2="DDI-PubMed.25923589.s23.e2" /><pair ddi="false" e1="DDI-PubMed.25923589.s23.e0" e2="DDI-PubMed.25923589.s23.e3" /><pair ddi="false" e1="DDI-PubMed.25923589.s23.e1" e2="DDI-PubMed.25923589.s23.e1" /><pair ddi="false" e1="DDI-PubMed.25923589.s23.e1" e2="DDI-PubMed.25923589.s23.e2" /><pair ddi="false" e1="DDI-PubMed.25923589.s23.e1" e2="DDI-PubMed.25923589.s23.e3" /><pair ddi="false" e1="DDI-PubMed.25923589.s23.e2" e2="DDI-PubMed.25923589.s23.e2" /><pair ddi="false" e1="DDI-PubMed.25923589.s23.e2" e2="DDI-PubMed.25923589.s23.e3" /></sentence><sentence text="" /></document>